Drug makers Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc. said Wednesday that they filed with the Food and Drug Administration for an expanded use of their Campath cancer drug.
The companies hope to get added approval for Campath as a first-line treatment for B-cell chronic lymphocytic leukemia, a type of blood cancer. Currently, the drug is approved to treat the disease in patients that have been treated with an alkylating agent and have failed fludarabine therapy.
The companies said the additional approval would significantly expand the target drug population.
Genzyme plans to make a similar filing within the next few weeks in Europe, where the drug is marketed as MabCampath.
Subscribe via RSS
